CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

MSCWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D007249 Inflammation NIH 0.20

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Prospective Phase II Study: MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDS

To evaluate the safety, toxicity and immunological effects of infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells (MSCs) and whether this therapy has an influence on the resolution processes in ARDS patients infected with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

NCT04377334 ARDS COVID-19 Biological: MSC
MeSH:Inflammation

Primary Outcomes

Description: improvement of lung injury score (LIS), 0-16 points, severity increasing with higher points

Measure: lung injury score

Time: day 10

Secondary Outcomes

Description: D-dimers blood levels

Measure: D-dimers

Time: day 0, 1, 2, 3, 10 and 15

Description: distribution of phenotypes of immune cells

Measure: phenotype

Time: day 0, 1, 2, 3, 10 and 15

Description: Levels of specialized pro-resolving lipid mediators within alveolar macrophages and bronchoalveolar lavage

Measure: pro-resolving lipid mediators

Time: day 0, 1, 2, 3, 10 and 15

Description: Cytokine concentration within bronchoalveolar lavage and Serum prior and after MSC infusions

Measure: cytokines

Time: day 0, 1, 2, 3, 10 and 15

Description: Chemokine concentration within bronchoalveolar lavage and Serum prior and after MSC infusions

Measure: chemokines

Time: day 0, 1, 2, 3, 10 and 15

Description: Survival at 10 days and 28 days

Measure: Survival

Time: day 10 and 28

Description: Time to removal of endotracheal tube

Measure: extubation

Time: day 28

Description: lymphocyte subpopulations in peripheral blood by flow cytometry prior and after MSC infusion (day 0,3,5,10)

Measure: lymphocyte subpopulations

Time: day 0, 3, 5 and 10

Description: evaluate SARS-CoV-2-specific antibody titers in the serum of patients prior and post MSC infusion.

Measure: SARS-CoV-2-specific antibody titers

Time: day 0, 5 and 10

Description: evaluate levels of complement molecules (C5-C9) in the serum of patients prior and post MSC infusion

Measure: complement molecules (C5-C9)

Time: day 0, 5 and 10

No related HPO nodes (Using clinical trials)